<SEC-DOCUMENT>0001104659-24-098148.txt : 20240909
<SEC-HEADER>0001104659-24-098148.hdr.sgml : 20240909
<ACCEPTANCE-DATETIME>20240909161520
ACCESSION NUMBER:		0001104659-24-098148
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240909
FILED AS OF DATE:		20240909
DATE AS OF CHANGE:		20240909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		241287427

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2423601d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of September 2024</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Form 20-F</FONT> <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp; &nbsp; <FONT STYLE="font-size: 10pt">Form 40-F</FONT> <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 9, 2024, CureVac N.V. (the &#8220;Company&#8221;) issued
a press release announcing the upcoming presentation of the first clinical data from the Company&#8217;s ongoing Phase 1 CVGBM cancer
vaccine study in patients with resected glioblastoma at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September
13-17, 2024).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 6-K (including
Exhibit 99.1, but excluding the statements of the Company&#8217;s Chief Scientific Officer contained in Exhibit&nbsp;99.1 hereto) is hereby
incorporated by reference into the Company&#8217;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 26%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    <TD STYLE="vertical-align: top; width: 21%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 9, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><A HREF="tm2423601d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><A HREF="tm2423601d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated September 9, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2423601d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2423601d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac to Present First CVGBM Glioblastoma
Cancer Vaccine Clinical Data<BR>
at ESMO 2024 Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>T&Uuml;BINGEN, Germany/BOSTON, USA</B> &ndash;
<B>September 9, 2024 </B>&ndash; CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical company developing a
new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today announced that the first clinical
data from CureVac&rsquo;s ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European
Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024). Clinical data will be presented as an oral presentation
on Friday, September 13, along with a poster presentation of preclinical data supporting the program&rsquo;s development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Cancer vaccines have tremendous potential
to improve the outcome of cancer patients and particularly, mRNA technologies offer innovative and promising platforms that could enable
us to finally make cancer vaccines a reality in clinical practice,&rdquo; said Dr. Myriam Mendila, Chief Scientific Officer of CureVac.
&ldquo;We are assessing a breakthrough approach to cancer vaccines that uses our distinctive mRNA technology in one of the most aggressive
forms of brain cancer and are very excited to share the first-in-human results of our mRNA technology platform in the GBLM trial in glioblastoma
at ESMO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 1 study includes a dose-escalation part
(Part A) and dose-expansion part (Part B). Results for Part A will be covered in the oral presentation, with safety and tolerability as
well as initial immunogenicity data provided for all evaluable patients at dose levels of 12-100 &micro;g. A summary of treatment-emergent
adverse events (TEAEs), which were mostly Grade 1-2 and yielded no dose-limiting toxicities as confirmed by a Data Safety Monitoring Board,
will also be provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 1 study is evaluating the safety and
tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-promoter unmethylated glioblastoma or astrocytoma
with a molecular signature of glioblastoma. CVGBM features a single unmodified mRNA encoding eight epitopes derived from known tumor-associated
antigens, with demonstrated immunogenicity in glioblastoma. Enrollment began earlier this year for Part B of the study, which is expected
to include up to an additional 20 patients at the recommended 100 &micro;g dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details on the presentations are below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Abstract: </B>440O</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Title: </B>First in human study of the mRNA-based
cancer vaccine CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from
the dose escalation phase</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Session type:</B> Proffered Paper</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date and Time:</B> September 13, 14:00-14:10
CEST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Location:</B> Pamplona Auditorium (Hall 3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Speaker:</B> Prof. Dr. Dr. Ghazaleh Tabatabai</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2423601d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Abstract: </B>22P</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Title: </B>Pre-clinical development of CVGBM:
A therapeutic mRNA-based multiepitope vaccine for glioblastoma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Session type:</B> Basic Science Poster</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date and Time:</B> September 15, 09:00-17:00
CEST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Location:</B> Hall 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Speaker:</B> Dr. Ronja I. M&uuml;lfarth</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac (Nasdaq: CVAC) is a pioneering multinational
biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than
two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced
and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying
the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined
with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates.
It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins.
Headquartered in T&uuml;bingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information
can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CureVac Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><IMG SRC="tm2423601d1_ex99-1img01.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that
constitute &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation
Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss
AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the
&ldquo;company&rdquo;) regarding future events or future results, in contrast with statements that reflect historical facts.
Examples include discussion of the potential efficacy of the company&rsquo;s vaccine and treatment candidates and the
company&rsquo;s strategies, financing plans, cash runway expectations, growth opportunities and market growth. In some cases, you
can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or
&ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
&ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are
based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However, these
forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding,
ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any
products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation
proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate
and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements
included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any
obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect
future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2423601d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2423601d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! *D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BD9E1"S
ML%4#)). !7*:CXYMH9S;:;;M>RYVA@<*3[=VK*K6A25YNQO1P]2L[4U<ZRF^
M8GF"/>N\C.W/./I7'-8>+-;0?:KJ.P@;GRTR&_3G\":TM"\*1:+>-=F[EGG9
M"A)4 <X^I[>M91K3G)<L';N]/P-IX>E3B^:HG+LM?QV.AHHHKJ.(**** "BB
MB@ HHK+\0:S'H.D2WKJ'886-,XW,>@_K^%-)MV1,YJ$7*6R*NH^+-/T[5ETQ
MHKFXNF .RWC#X)[=<YQS3_\ A*M/3_CXCO;;_KM:2#^E8W@C2V$<WB'4&'VJ
M]8E"W&U2>OXGI[8]:[2M9J$7RVN<M&5:I'G;M?96Z=+ZF9;^(]&N3B+4[7=_
M=:0*?R.#6DK*ZAE8,IZ$'(J&XLK2[&+FUAF'_32,-_.L63P9I:R&6Q:YT^4G
M.ZUF*\_0Y&/:HM!^1JW671/\/SN=#16 8?$E@/W-S:ZG&/X)U\J3Z!A\I_$4
MNF>*[*_O#83QRV5^.#!<#&3['O1R.UUJ"KQNHRT;[_Y[&]1114&X4444 <'X
M_P!0G%S;:9&Y2)T$C\X#$D@ ^PQ74:)H=KHMFL<2*9B/WDV.7/\ A[54\3^'
M5URT#Q$+=Q ^6QZ,/[IK$TWQ-?Z"R:?KUM*$482;&2!_)A[C]:\QM4L1*=5:
M/9]%Y>1[*3KX2-.@]5NNK\_,[JL#1V8^*=?4L2 8< GI\IK2LM8T[4 /LMY#
M(3_"&PWY'FLNYTW6+/6;J^TEK1UNPGF)<[OE*C QBNJI*_+..J3Z:]&<-&/+
MSTY^ZVNNG5/L7/$S%?#=^5)!$7!'UK"\3R;?"^CL[LJF2+>02.-ASTJU=VGB
MC4[5[.Y_LR*"7Y7>/>6 ]LU:US1)K[3;"TMBA%M,C'S#C*J"/SK"JI5%-Q3V
M2U]3JH.%%P4I+XF]'TM;L9!?P5M/^DO^$LW^-3Z-+>P>"=0G>28,!*]L\A.X
M)M^4\^^:Z8V%F00;2 @]1Y8K&T;09[7P[=Z9=NH\]I IC.0JL ._XT>QG&>B
M6SVT^_\ 0/K%.5.S;WCN[Z7UMI]YAV']C26%N]UIVK33M&#)(HE(9L<D$-TK
M<TW3=)OK"[B@M+R"*4!)!.SJ3W!&XGIZU#:P>*K&UBM(5TJ2*%0B,V_) X&:
MT],;73<-_::6*P[/E-ONW;LCU[8S1AX\LHW3O_AM^-PQ4E.$DI)I_P!Z^GI8
MY3PSJ-QX=\03^'-3D9HY'S;RL<\GI^#?H:B9SXZ\7"(9;1[ Y;!P)/\ ]9'Y
M"M_QCX;76]/\^W3_ (F, S$P."PSRI_I[TZUT*YT3PPUGHPB74'4;YI#P6/5
MNAZ=A7M\\;<Z^)Z?\$^3]A53]E+6"U\VND?O_ H:I:R>*=4?2;28P:;IZXF9
M. TV/E4>R\?YQ6IX9UB2_MY;&]!74K$^5< _Q>C#U!Q4-EX)TB&TC6Y@>>Y(
MS+*9G&]SU/!]:9+X8&EZA:ZAH$:12JQ6XBDE;;+&>O)SR,#%2Y0:Y;^G]>9M
M&%:$O:M;[Z].EEY?YE:/3X-<\8:U#J#32Q6HA$,8F9%7<N3]TCO6HGA#1$=7
M6VE#*<C_ $F7_P"*JI=Z5KEEKUYJ.C/8NMZJ>;'=;OE*C QBG1R>,_,7S(=&
MV9&[!DSCOWH;;^&6GJ$8PBVITVW=ZVOUTUN=+63K^AVVMZ=)#*BB=5)AE_B1
MNW/I6I)+'#&TDKJB*,EF. /QKD=7\2S:LKZ7X:C>YG?*270&(XAWPWK[_EFL
MJ<9-WB=.(G34'&>M^G5B?#W6KG4]+N+>[D:62U90)&.258' )[XP?TKL:Q/#
M'AZ/P[IGD!A)<2'?-(.A/H/85MT57%S;CL&%C.-&,:FX4445F= 4R6&*>,QS
M1I(AZJZ@@_A3Z*-P3MJCEKWP'I=PS/;O-:N3D!3N4?@>?UJ;0M!U+1[XF74S
M<V90@1L2,-Q@X.0._>NCHKF6%I*7/%6?D=;QM>4'3E*Z\]?^"%%%%=)R!115
M2]LK*_,<-VBN1ET3>0>P)X/N/SIKS$[VT+=%<_'I>B2:K<::D$XG@ACG?$T@
M7:[.JX.[KF-OTJU_PC6EGK#-_P"!4O\ \53M'N9WJ=E]_P#P#6I&94&68 >I
M-8=UH7A^SMWN+Q$A@09>2>Y8*H]RS8JEID/@?5IVBTR71K^5!ED@G29@/4@$
MT[1[A>KV7W_\ WY=4T^#_77]K'_OS*/YFJ4GBK0XSC^TH9#Z19D/_CH-3G2M
M%LHS(;"Q@1<9<PHH'.!SBKZ1I$N$14'HHQ1[GF+]Z^R^_P#X!SS^*I96*Z?H
M6I70[2-%Y2'\6_PIZ/XIOUSY5CIB'^\3/(/RPM=!13YTMD+V4W\4W\K+_@_B
M<U_PAMO=SBXUB^NM2E!SMD;9&/HHZ?G710PQ6\2Q0QI'&HPJ(H 'X"GT5,IR
MENRH4H0UB@HJI:WK7-[?0>242UD6/S"WWV**YP/0!E_'/I6?J'B6&QU%;(6L
MTSEMN5Q\S84[5]3AU/.!SUX.)-3;HJGI6K6.N:;#J.FW*W-G-N\N5,X;!*GK
M[@BKE !1110 4444 %%%% !7-ZT=6@UJ#4+:R@:""*2W\X%Y7"R;&+&)0"0#
M&!@,3SG KI** .6MCK<T]T]O#$+BYCC"ZG);F.(*N>/)+^9D$M@$@<YW=JIZ
MQ?>(=3TJWM+9+S1[EY&AN;J.V,NQU*?,@ 8E&!<J>.0 2.0>UHH R]<L&OO#
MEY:QQI/<&W;R/.16_>A3L8@C&=V#TK'GBU >(%EO-)>32[<)+IXL=F4?:0WF
M@D-G)( 7*XZ\XQUE% '&ZM<7.I:)KMG?V=VUO?K+!91+;.74A3'M8J#MRZ[U
M8X&'ZX%,N;?Q#JEVEI>Z-#=:=;PK$T=U<*D5U-M&Z1\!B4'15VG)R2!A37:T
M4 8WAJWU6RT^2SU58B89"+=XI3(#">54E@"2OW<D<@ ]2:H27^LZAK<Z:<YB
MAL;Z.WECVHR.FV-Y"Y/S E)/E"]UY^]@=15&TTQ+35-0O4E<_;3&SQGHK*NW
M(^JA1_P&@#CEN?'%S:7E] K133&.);)X5)M?F.]UW!%<A<*/G(;ELCA:UIYM
M;BAALH1<K/)%+,A5HGD4[U"JQ<[2 &RV"3T )QSU-4+RRGFU/3;J"8(MO(XF
M4_\ +2-D(P/?>(S^!H YO5I-?2RNXHX98IIWP\]J'(1_)B 8;5+E-V_[HSE0
M"0"36J_AF"X:">2\N_/5%#R+M#.VU5+\J2K$*H.TC@5O44 5=.TZSTFQCL=/
MMH[:UBSLBB7"KDDG ^I)_&K5%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
